Hair Loss Treatment Solution
Treatment of Alopecia – Lipid based Morr F Technology Alopecia or hair loss is most prevalent in male population. More specifically men lose hair from the scalp and to lesser extent from other parts of the body. The most common type of hair loss leading to appearance of male baldness is called Androgenetic Alopecia. It is characterized as hair loss from the scalp which affects majority of male population where almost 50% hair loss occurs to some degree by age 50. Such a pattern of hair loss occurring in male population is related to genetic factors however the mechanism of hairs loss is still not clearly understood. So far, the two drugs approved by the US FDA for treatment of androgenetica alopecia are:
- Minoxidil (a potassium channel opener and had benefited by increasing hair growth). This topical drug is a commonly used for the local treatment of baldness and it arrest the progress of hair loss. However, in most studies it was found that baldness progressed if the treatment in stopped. The mechanism of action is not well understood but it is speculated that it enhances the blood vessels for better flow of blood and opens the potassium channels, it allows more oxygen and nutrients tohair follicles. This can also cause follicles in the telogen phase to shed, usually soon to be replaced by new, thicker hairs (in a new anagen phase).
- Finasteride (an oral drug acts as a potent 5-reductase type 2 inhibitor lowering dihydrotestosterone and prevents hair loss). The hormone testosterone in males is produced primarily in the testes and also in adrenal glands. The majority of testosterone is bound to sex hormone-binding globulin (SHBG), a protein produced in the liver that transports testosterone in the bloodstream thus prevents its metabolism and prolongs the half-life. Once testoterone becomes unbound from SHBG, it enter cells throughout the body. In certain tissues, such as scalp, skin, and prostate, testosterone is converted into dihydrotestosterone by the 5-alpha reductase. By blocking the action of 5-alpha reductase, finasteride blocks the conversion of testosterone into androgen ddihydrotestosterone. This reduces androgenic activity in the scalp, treating hair loss at its hormonal source. Finasteride lowers the circulation of dihydrotestosterone by inhibiting the production of prostate and does not affect the metabolism of the androgen in the hair follicle and helps to reduce the risk of prostate cancer.
In view of the different mechanisms of action, it has been suggested that the simultaneous administration of both the molecules should have a dual affect resulting in better treatment effect. Finasteride formulated for topical use will reduce the systemic exposure of Finasteride leading to less adverse effect on the reproductive system i.e. less incidence of loss of libido, erectile dysfunction, ejaculation disorders, breast engorgement or tenderness and effects on testis. The side effects associated with the oral administration would also be reduced if the treatment is localized to the affected area. In addition, lower dosage of Finasteride could further improve the safety profile of the therapy.
To accomplish the combination effect of Minoxidil and Finasteride, Morr F Technology was developed that is based on the mixture of Minoxidil and Finasteride with lipid ingredient. The high and reproducible drug uptake of skin is proven in the presence of lipid carriers. The lipid used is a supplier of highly unsaturated lipids that helps in forming a reservoir on the skin prolonging the penetration of drugs.
Clinical studies indicated that it MorrF can help to induce hair growth in men.